Cabozantinib

Cabozantinib is used to treat renal cell carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. Cabozantinib is given in tablet form and is Available in all of UK. The combination therapy of Cabozantinib and Nivolumab (Opdivo) has been made available for patients as a first line treatment in Scotland from October 2021. The NICE appraisal for the combination treatment for the rest of the UK was terminated  in 2020.

Delivery: Tablet
Availability: UK